EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study

Joseph F Merola iD, Albert S Chiou iD, Emmanuel During iD, Antonio Costanzo iD, Peter Foley, Amani Alfalasi iD, Shaila Gogate, Andreas Pinter, Roni Dodiuk-Gad iD, Dagmar Simon iD, Marie Tauber iD, Richard Weller iD und 4 weitere

British Journal of Dermatology · 2023

DOI: 10.1093/bjd/ljad284 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Joseph F Merola und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi and Regeneron Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sleep disturbance is a prominent symptom of atopic dermatitis (AD) and can result in insomnia, daytime fatigue, drowsiness, reduced productivity and impaired quality of life (QoL).

Objectives

The Dupilumab Effect on Sleep in AD Patients (DUPISTAD) phase IV randomized double-blinded placebo-controlled study evaluated the impact of dupilumab treatment on sleep and other patient- and physician-reported outcomes.

Methods

Adults with moderate-to-severe AD were randomized 2 : 1 to dupilumab 300 mg once every 2 weeks (q2w) or placebo for 12 weeks; concomitant topical corticosteroids were permitted. Patients subsequently entered an open-label phase and received dupilumab 300 mg q2w for a further 12 weeks. The primary endpoint was the percentage change in sleep quality from baseline to week 12, assessed using a novel numeric rating scale (NRS). Secondary and exploratory endpoints included percentage change in peak pruritus NRS (PP NRS), change in SCORing Atopic Dermatitis (SCORAD), SCORAD sleep visual analogue scale (VAS), Eczema Area and Severity Index, Patient-Reported Outcomes Measurement Information System (PROMIS) sleep-related impairment T-score and the Epworth Sleepiness Scale. Sleep diary and wrist actigraphy measurements were recorded throughout the study.

Results

In total, 127 patients received dupilumab and 61 patients received placebo. Demographic and baseline disease characteristics were balanced between groups. Sleep quality NRS significantly improved in patients treated with dupilumab by week 12 vs. placebo [least squares mean of the difference (LSMD) −15.5%, P < 0.001]. PP NRS (LSMD −27.9%, P < 0.001), SCORAD (LSMD −15.1, P < 0.001), SCORAD sleep VAS (LSMD −2.1, P < 0.001) and PROMIS T-score (LSMD −3.6, P < 0.001) were also significantly improved at week 12 with dupilumab vs. placebo. The overall percentage of patients reporting treatment-emergent adverse events was lower in the dupilumab group (56.7%) than in the placebo group (67.2%).

Conclusions

Dupilumab significantly improved sleep quality and perception of sleep continuity, itch, metrics of AD severity and QoL in adults with moderate-to-severe AD, with an acceptable safety profile compared with placebo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAdultHumansAntibodies, MonoclonalDouble-Blind MethodInjections, SubcutaneousPruritusQuality of LifeSeverity of Illness IndexSleepTreatment OutcomeAntibodies, Monoclonal, Humanized

Substanzen

Antibodies, MonoclonaldupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
  • Harvard Medical School, Boston, MA, USA.
  • Department of Dermatology, Stanford University, Palo Alto, CA, USA.
  • Department of Neurology & Neurological Sciences, Stanford University, Palo Alto, CA, USA.
  • Department of Psychiatry and Behavioral Sciences, Division of Sleep Medicine, Stanford University, Palo Alto, CA, USA.
  • Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

ORCID-Profile: Joseph F Merola, Albert S Chiou, Emmanuel During, Antonio Costanzo, Amani Alfalasi, Roni Dodiuk-Gad, Dagmar Simon, Marie Tauber, Richard Weller, Jose-Juan Pereyra-Rodriguez, Marius Ardeleanu

Förderung

  • Sanofi and Regeneron Pharmaceuticals Inc

Zitieren

APA

Merola, J. F., Chiou, A. S., During, E., Costanzo, A., Foley, P., Alfalasi, A., Gogate, S., Pinter, A., Dodiuk-Gad, R., Simon, D., Tauber, M., Weller, R., Pereyra-Rodriguez, J. J., Ardeleanu, M., Wu, J., & Ozturk, Z. E. (2023). Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad284

Vancouver

Merola JF, Chiou AS, During E, Costanzo A, Foley P, Alfalasi A, et al. Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad284

BibTeX
@article{Merola2023,
  author = {Merola, Joseph F and Chiou, Albert S and During, Emmanuel and Costanzo, Antonio and Foley, Peter and Alfalasi, Amani and Gogate, Shaila and Pinter, Andreas and Dodiuk-Gad, Roni and Simon, Dagmar and Tauber, Marie and Weller, Richard and Pereyra-Rodriguez, Jose-Juan and Ardeleanu, Marius and Wu, Jiangming and Ozturk, Zafer E},
  title = {Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study},
  journal = {British Journal of Dermatology},
  year = {2023},
  doi = {10.1093/bjd/ljad284}
}
Kostenlos starten →